| Duke University, BA |
David is one of the co-founders of De Novo. Prior to co-founding De Novo, David was a Partner at Asset Management Company, where he worked with Pitch Johnson as the lead partner in healthcare investments. At AMC, he led seed and early stage investments in TriVascular (acquired by Boston Scientific), Novare Surgical Systems (licensed to Johnson & Johnson), Enteric Medical Technologies (acquired by Boston Scientific), and participated in seven financings of technology companies. David was the first employee and Director of Business Development for Fox Hollow Technologies (Nasdaq: EVVV) and worked in product management for Heartport (acquired by Johnson & Johnson). He earned his MD degree from The Dartmouth School of Medicine and a BA from Duke University.
David sits on the boards of Articulinx, Applied Spine, ProMed, Simpirica, TRIA Beauty, VeinRx and Ventus Medical. He also represented De Novo on investments in CyroVascular, Lumend and Paracor Medical.
